DT-216P2

DT-216P2 is an investigational small-molecule drug candidate developed by Design Therapeutics for the treatment of Friedreich's ataxia (FA).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

DT-216P2 is an investigational small-molecule drug candidate developed by Design Therapeutics for the treatment of Friedreich's ataxia (FA). It is a "GeneTAC" (gene-targeted chimera) compound designed to increase expression of frataxin by targeting the expanded GAA trinucleotide repeat in the FXN gene, the genetic cause of the disease.

As of 2026 it is in Phase 1/2 clinical testing and has not been approved for medical use in any country. DT-216P2 is a reformulation of the first-generation candidate DT-216, developed after injection-site reactions limited the earlier compound. It can be administered by intravenous infusion or by subcutaneous injection or infusion.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1361137144 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.